These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35677177)

  • 21. The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.
    Li S; Liu J; Wang Z; Duan F; Jia Z; Chen X; Li S
    Front Public Health; 2022; 10():862266. PubMed ID: 35958869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Tang Y; Huang J; Zhang WY; Qin S; Yang YX; Ren H; Yang QB; Hu H
    Therap Adv Gastroenterol; 2019; 12():1756284819878046. PubMed ID: 31598135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.
    Kanchanasurakit S; Kositamongkol C; Lanoi K; Nunta M; Saetuan T; Chaiyakunapruk N; Saokaew S; Phisalprapa P
    Front Nutr; 2022; 9():880014. PubMed ID: 35669067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised placebo controlled trial of VSL#3
    Chong PL; Laight D; Aspinall RJ; Higginson A; Cummings MH
    BMC Gastroenterol; 2021 Apr; 21(1):144. PubMed ID: 33794784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial.
    Behrouz V; Aryaeian N; Zahedi MJ; Jazayeri S
    J Food Sci; 2020 Oct; 85(10):3611-3617. PubMed ID: 32885440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Guo XF; Wang C; Yang T; Li S; Li KL; Li D
    Food Funct; 2020 Sep; 11(9):7389-7399. PubMed ID: 32966467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Relationship between Prebiotic Supplementation and Anthropometric and Biochemical Parameters in Patients with NAFLD-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Stachowska E; Portincasa P; Jamioł-Milc D; Maciejewska-Markiewicz D; Skonieczna-Żydecka K
    Nutrients; 2020 Nov; 12(11):. PubMed ID: 33187278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Benefit of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: A Meta-analysis of Randomized Control Trials.
    Gkiourtzis Ν; Kalopitas G; Vadarlis A; Bakaloudi DR; Dionysopoulos G; Karanika E; Tsekitsidi E; Chourdakis M
    J Pediatr Gastroenterol Nutr; 2022 Sep; 75(3):e31-e37. PubMed ID: 35758473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Wang ST; Zheng J; Peng HW; Cai XL; Pan XT; Li HQ; Hong QZ; Peng XE
    BMC Gastroenterol; 2020 Mar; 20(1):66. PubMed ID: 32164541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial.
    Kobyliak N; Abenavoli L; Mykhalchyshyn G; Kononenko L; Boccuto L; Kyriienko D; Dynnyk O
    J Gastrointestin Liver Dis; 2018 Mar; 27(1):41-49. PubMed ID: 29557414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Wang Q; Wang Z; Pang B; Zheng H; Cao Z; Feng C; Ma W; Wei J
    Front Endocrinol (Lausanne); 2022; 13():1014670. PubMed ID: 36407321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Zhou ST; Cui W; Kong L; Yang X
    Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
    Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
    Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology.
    Huang Y; Wang X; Yan C; Li C; Zhang L; Zhang L; Liang E; Liu T; Mao J
    Medicine (Baltimore); 2022 Oct; 101(43):e31437. PubMed ID: 36316840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Khalili L; Nammi S
    Curr Pharm Des; 2022; 28(23):1911-1925. PubMed ID: 35345991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.